191 related articles for article (PubMed ID: 34306045)
1. Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-
AlNafea HM; Korish AA
PPAR Res; 2021; 2021():5558731. PubMed ID: 34306045
[TBL] [Abstract][Full Text] [Related]
2. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.
Souza-Mello V
World J Hepatol; 2015 May; 7(8):1012-9. PubMed ID: 26052390
[TBL] [Abstract][Full Text] [Related]
5. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
6. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
7. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
Choudhary NS; Kumar N; Duseja A
J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
[TBL] [Abstract][Full Text] [Related]
9. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
11. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
12. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
13. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease.
Giby VG; Ajith TA
World J Hepatol; 2014 Aug; 6(8):570-9. PubMed ID: 25232450
[TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment effect of total flavonoids in Stellera chamaejasme L. on nonalcoholic fatty liver in rats.
Wang Y; Li JY; Han M; Wang WL; Li YZ
Lipids Health Dis; 2015 Aug; 14():85. PubMed ID: 26242978
[TBL] [Abstract][Full Text] [Related]
15. Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice.
Zhu SY; Jiang N; Yang J; Tu J; Zhou Y; Xiao X; Dong Y
Biomed Pharmacother; 2018 Apr; 100():191-197. PubMed ID: 29428667
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.
Nagaya T; Tanaka N; Kimura T; Kitabatake H; Fujimori N; Komatsu M; Horiuchi A; Yamaura T; Umemura T; Sano K; Gonzalez FJ; Aoyama T; Tanaka E
BBA Clin; 2015 Jun; 3():168-74. PubMed ID: 26674248
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
[TBL] [Abstract][Full Text] [Related]
18. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
19. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice.
Yamaguchi K; Nishimura T; Ishiba H; Seko Y; Okajima A; Fujii H; Tochiki N; Umemura A; Moriguchi M; Sumida Y; Mitsuyoshi H; Yasui K; Minami M; Okanoue T; Itoh Y
Liver Int; 2015 Feb; 35(2):550-61. PubMed ID: 25066281
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
